Get the Stockscreener App
4.79
2.54%
-0.125
After Hours:
4.80
0.010
+0.21%
Candel Therapeutics Inc stock is traded at $4.79, with a volume of 786.53K.
It is down -2.54% in the last 24 hours and down -24.57% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$4.915
Open:
$4.89
24h Volume:
786.53K
Relative Volume:
0.95
Market Cap:
$262.95M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-2.8343
EPS:
-1.69
Net Cash Flow:
$-31.03M
1W Performance:
-4.20%
1M Performance:
-24.57%
6M Performance:
-40.79%
1Y Performance:
-27.09%
1-Day Range:
$4.745
$4.9263
1-Week Range:
$4.745
$5.29
52-Week Range:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
4.79 | 266.24M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Candel Therapeutics (NASDAQ:CADL) Stock Rating Lowered by Wall Street Zen - MarketBeat
Acorn Capital Advisors LLC Purchases 212,608 Shares of Candel Therapeutics, Inc. $CADL - MarketBeat
Nuveen LLC Makes New $442,000 Investment in Candel Therapeutics, Inc. $CADL - MarketBeat
Candel Therapeutics (NASDAQ:CADL) Lowered to Neutral Rating by Bank of America - MarketBeat
Candel Therapeutics: Potentially The Next Exciting Oncology Story - Seeking Alpha
Can Candel Therapeutics Inc. be recession proofQuarterly Performance Summary & Weekly Setup with ROI Potential - 뉴스영
What MACD and RSI say about Candel Therapeutics Inc.July 2025 Earnings & Low Risk Entry Point Guides - Newser
Baker BROS. Advisors LP Cuts Holdings in Candel Therapeutics, Inc. $CADL - MarketBeat
How volatile is Candel Therapeutics Inc. stockWeekly Market Outlook & Smart Allocation Stock Tips - 더경남뉴스
What are Candel Therapeutics Inc.’s earnings expectations2025 Sector Review & Daily Stock Trend Watchlist - خودرو بانک
Can Candel Therapeutics Inc. expand its profit marginsWeekly Trend Report & Real-Time Market Sentiment Alerts - خودرو بانک
What is Candel Therapeutics Inc.’s valuation compared to sectorEarnings Recap Report & Real-Time Volume Surge Alerts - خودرو بانک
Dow Update: Is Candel Therapeutics Inc. benefiting from interest rate changesTake Profit & Verified Technical Signals - خودرو بانک
Will Candel Therapeutics Inc. benefit from macro trendsWeekly Trade Summary & Reliable Intraday Trade Plans - Newser
Pattern recognition hints at Candel Therapeutics Inc. upsideTrade Volume Summary & Precise Buy Zone Identification - Newser
Insider Purchases Worth US$3.00m See Losses As Candel Therapeutics Market Value Drops To US$280m - 富途牛牛
Advanced analytics toolkit walkthrough for Candel Therapeutics Inc.2025 Market Outlook & Weekly High Momentum Picks - Newser
Should I average down on Candel Therapeutics Inc. stockRate Cut & Free Real-Time Market Sentiment Alerts - خودرو بانک
Candel Therapeutics: Revolutionizing Solid Tumor Treatment with Viral Immunotherapies - AInvest
Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors - Seeking Alpha
How to track smart money flows in Candel Therapeutics Inc.Share Buyback & Consistent Return Strategy Ideas - Newser
Chart based analysis of Candel Therapeutics Inc. trendsJuly 2025 Market Mood & AI Forecasted Stock Moves - Newser
Candel Therapeutics Inc. stock daily chart insights2025 Market Overview & Long-Term Growth Portfolio Plans - Newser
Multi asset correlation models including Candel Therapeutics Inc.July 2025 Momentum & Free Expert Approved Momentum Trade Ideas - Newser
What’s next for Candel Therapeutics Inc. stock2025 Key Highlights & Entry Point Confirmation Signals - خودرو بانک
What momentum shifts mean for Candel Therapeutics Inc.Market Weekly Review & AI Powered Market Entry Ideas - Newser
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
How hedge fund analytics apply to Candel Therapeutics Inc. stockPortfolio Risk Summary & Expert Curated Trade Setup Alerts - Newser
How high can Candel Therapeutics Inc. stock go2025 Bull vs Bear & Stock Market Timing Techniques - Newser
Is Candel Therapeutics Inc. stock heavily shortedEarnings Risk Summary & Target Return Focused Stock Picks - خودرو بانک
Candel Therapeutics: Assessing the Impact of BofA's Downgrade on a Promising Biotech - AInvest
Candel Therapeutics Falls After Downgrade From BofA Securities - MarketScreener
Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts - Seeking Alpha
Candel Therapeutics shares fall 15.79% intraday after BofA Securities downgrades the stock. - AInvest
What does recent volatility data suggest for Candel Therapeutics Inc.Forecast Cut & AI Enhanced Trade Execution Alerts - Newser
Candel Therapeutics Downgraded to Neutral by B of A Securities - AInvest
Price action breakdown for Candel Therapeutics Inc.July 2025 Selloffs & Precise Swing Trade Alerts - Newser
BofA Securities Downgrades Candel Therapeutics to Neutral From Buy - MarketScreener
Candel Therapeutics shares rise 1.71% after-hours after appointing renowned immunotherapy expert Carl H. June to its Research Advisory Board. - AInvest
Rally Mode: Is Candel Therapeutics Inc. forming bullish engulfing patternsJuly 2025 Macro Moves & AI Powered Market Entry Strategies - خودرو بانک
Small Cap Stocks Gain Traction: MustGrow Biologics, Ocean Power Technologies, Medicus Pharma, Candel Therapeutics, Digi Power X, and G Mining Ventures Lead the Way - AInvest
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):